Cite
HARVARD Citation
Kantarjian, H. et al. (2019). Inotuzumab ozogamicin versus standard of care in relapsed or refractory acute lymphoblastic leukemia: Final report and long‐term survival follow‐up from the randomized, phase 3 INO‐VATE study. Cancer. 125 (14), pp. 2474-2487. [Online].